EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025.08.13

Date

Title

2019-01-10

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

2018-10-30

Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics

2018-10-29

Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018

2018-08-22

Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China

2018-08-10

Group Turnover and Profit in the First Half of 2018 Increased 28.3%

2018-07-24

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-18

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

2018-04-12

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT